"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 2 | 3 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Lopez-Candales A, Vallurupalli S. PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities. JAMA Cardiol. 2021 04 01; 6(4):480-481.
-
Torres E, Goicoechea M, Hern?ndez A, Rodr?guez Ferrero ML, Garc?a A, Mac?as N, Anaya F. Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). J Clin Apher. 2020 Jan; 35(1):9-17.
-
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019 08 24; 394(10199):672-683.
-
Yu J, Li X, Matei N, McBride D, Tang J, Yan M, Zhang JH. Ezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK dependent autophagy activation after MCAO in rats. Exp Neurol. 2018 09; 307:12-23.
-
White CM, Weeda ER, Nguyen E. Should an LDL-Cholesterol Target-Based Approach Be Readopted? Ann Pharmacother. 2018 02; 52(2):175-184.
-
Quintana AM, Hernandez JA, Gonzalez CG. Functional analysis of the zebrafish ortholog of HMGCS1 reveals independent functions for cholesterol and isoprenoids in craniofacial development. PLoS One. 2017; 12(7):e0180856.
-
Juarez DT, Tan C, Davis JW, Mau MM. Using quantile regression to assess disparities in medication adherence. Am J Health Behav. 2014 Jan; 38(1):53-62.
-
Hsia SH, Desnoyers ML, Lee ML. Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States. J Clin Lipidol. 2013 Nov-Dec; 7(6):675-82.
-
Bereal-Williams C, Machado RF, McGowan V, Chi A, Hunter CJ, Kato GJ, Hunter L, Dalby CK, Hauser KP, Tailor A, Cannon RO. Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. Haematologica. 2012 Nov; 97(11):1768-70.
-
Arimura T, Miura S, Ike A, Sugihara M, Iwata A, Nishikawa H, Kawamura A, Saku K. Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol. 2012 Aug; 60(2):111-8.